Hundreds of billions of dollars in the API market, who is the main floating?

Pharmaceutical Network Market Analysis: API is the basic link in the pharmaceutical industry chain, and its quality is closely related to the nature of all aspects of the drug.
, with the rapid development of the biopharmaceutical industry, the market size of API has also grown.
according to the "2020-2024 China's API Industry In-depth Research and Investment Prospects Forecast Report" released by CIC Industry Research Institute, china's API market reached about 257.929 billion yuan in 2019, up 6.4% YoY.
, what about the current API track? Who is the main floating in a market of hundreds of billions of dollars? Some industry analysts believe that in the short term, the API industry is difficult to become the pharmaceutical industry more core investment main line.
but in the long run, the growth attributes of the specialty API industry are becoming clearer, and there are still more medium- and long-term opportunities in the industry.
especially since this year, by the impact of the special period, the global API industry has undergone some significant changes, may bring opportunities to domestic API enterprises.
on the one hand, with the rising cost of environmental protection, labor costs, the logic of the global API industry has changed, the production capacity of specialty API is gradually shifting to the Asia-Pacific region, the domestic API industry also ushered in a higher degree of prosperity.
, according to related reports, the domestic market is expected to reach about 5.5 billion U.S. dollars in specialty raw materials.
years, specialty API is accelerating the transfer to the domestic, superimposed on the impact of this year's special period, some varieties of prices may be expected to rise.
On the other hand, with the promotion of policies such as drug association review, normalization of collection and collection, and consistent evaluation, the position of API in the industry has gradually been enhanced, and the importance of high-quality standards of specialty API to downstream preparations has been highlighted, which has also led to the promotion of the voice of API in the industrial chain, and with the new medical insurance reform, the API industry has greater room for growth.
the current domestic API industry there is still a small, scattered, chaotic situation, low-cost competition between enterprises, waste of resources serious, overcapacity problem is increasingly prominent.
industry expects that under the dual pressure of industry integration and environmental upgrading, at least 70% of SMEs will disappear in the future, while API- and CDMO companies with large-scale effects will be expected to win in the 100 billion market.
in fact, API companies' future is generally promising in the industry in the trend of innovation.
that since 2019, innovative pharmaceutical companies, generic API and CDMO companies more and more cases of cooperation.
Among them, in the field of API-plus preparations, related companies include Huahai Pharmaceuticals, Novaral, Berry Pharmaceuticals, Pro Pharmaceuticals, Steyr, Oxiang Pharmaceuticals, etc., and in the field of API-CDMO, related companies such as Kaileiying, Jiuzhou Pharmaceuticals, Boten Ag, Manova, Pro Pharmaceuticals, etc.
, it is understood that Prop Pharmaceuticals and other joint reviews more, which also reflects the CDMO leader in the field of innovative API, difficult API has outstanding advantages.
industry believes that in the field of process amplification and cost management involved in the commercial production of innovative pharmaceuticals, some of the api-CDMO enterprises with strong production capacity will have obvious advantages.
, with the gradual deepening of strip procurement, generic drugs face the challenge of increasing production prices while ensuring quality.
industry believes that through the "raw materials and preparations" integrated development model, can also be to a large extent on the volume of procurement brought about by the impact of drug price reduction, and the value of this model has been further recognized by the market.
, for example, by realizing the integration of API preparations, The pharmaceutical industry has effectively solved the difficulties of the continuous supply instability of PPS, providing a prerequisite for the increase in sales volume.
is understood that the company's sodium hypochloride injection from 2017 to 2019, respectively, achieved sales revenue of 12.2315 million yuan, 61.1978 million yuan and 160 million yuan, one of the reasons for the rapid growth of the product is that the product achieved the integration of raw materials and preparations.